Evidence map›Paper›PMID 40025867›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Advancing Precision Medicine: Recent Innovations in Gene Editing Technologies.

Abhijith Koodamvetty, Saravanabhavan Thangavel

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. New Horizons in Metabolic Health: Unveiling the Future of Drug Discovery and Development.Endocrine, metabolic & immune disorders drug targets · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Advancing Precision Medicine: Recent Innovations in Gene Editing Technologies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Abhijith KoodamvettyCentre for Stem Cell Research (CSCR), A unit of InStem Bengaluru, Christian Medical College campus, Vellore, Tamil Nadu, 632002, India.ORCID https://orcid.org/0009-0006-8060-4470
Saravanabhavan ThangavelCentre for Stem Cell Research (CSCR), A unit of InStem Bengaluru, Christian Medical College campus, Vellore, Tamil Nadu, 632002, India.ORCID https://orcid.org/0000-0001-6760-4106

Funding

DBT/Wellcome Trust India Alliance IA/TSG/22/1/600431Department of Biotechnology, Ministry of Science and Technology, India BT/PR38267/GET/119/348/2020Wellcome Trust
6 · The paper itself

Abstract

The advent of gene editing has significantly advanced the field of medicine, opening new frontiers in the treatment of genetic disorders, cancer, and infectious diseases. Gene editing technology remains a dynamic and promising area of research and development. Recent advancements in protein and RNA engineering within this field have addressed critical issues such as imprecise edits, poor editing efficiency, and off-target effects. Advancements in delivery methods have allowed the achievement of therapeutic or even selection-free gene editing efficiency with reduced toxicity in primary cells, thereby enhancing the safety and efficacy of gene manipulation. This progress paves the way for transformative changes in molecular biology, medicine, and other fields. This review provides a comprehensive overview of the advancements in gene editing techniques, focusing on prime editor proteins and their engineered variants. It also explores alternative systems that expand the toolkit for precise genomic modifications and highlights the potential of these innovations in treating hematological disorders, while also discussing the limitations and challenges that remain.

Indexed as

Gene EditingGenetic TherapyPrecision MedicineAnimalsCRISPR-Cas SystemsHumansCRISPR‐Cas9gene editinghematological disordersprime editing

Identifiers

PMID40025867
PMCPMC11984848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.